Trevi Therapeutics reports positive SSRE for Phase 2b CORAL trial; sample size unchanged at 160 patients.

Trevi Therapeutics, Inc.

SSRE analysis on highest 108mg BID dose after 80 patients completed 6 weeks recommended continuing as planned; no sample size increase or futility.
Trial enrollment 75% complete; topline results from CORAL Phase 2b still expected in first half of 2025.
Pre-specified conditional power maintained at 80% or greater based on SSRE outcome.
Other two pre-specified SSRE outcomes (sample size increase or futility) were ruled out.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.